This is particularly significant for patients with fatty liver disease, metabolic syndrome, or those recovering from illness, where this clearance function is often impaired
"Valproic acid and HIV-1 latency: beyond the sound bite"
This signal extends well beyond CRC
In a study by Epic Research, over the course of just 60 weeks using GLP-1s, non-diabetic participants lost an average of 11% of their body weight while diabetics saw an impressive 8% reduction
& Berger, T
GLP-1 Agonists Like Semaglutide Show Promise in Reducing Alcohol Use Disorder, Study Finds Feb 20, 2025 2 min read Updated: Nov 6, 2025 Recent research suggests that semaglutide, a medication primarily used for type 2 diabetes and weight management, may also help reduce alcohol consumption